{"id":23537,"date":"2023-02-24T04:56:00","date_gmt":"2023-02-23T20:56:00","guid":{"rendered":"http:\/\/csccm.org.cn\/?p=23537"},"modified":"2023-02-24T09:31:34","modified_gmt":"2023-02-24T01:31:34","slug":"jama%e5%8c%bb%e5%ad%a6%e6%96%b0%e9%97%bb%ef%bc%9a%e5%85%8d%e7%96%ab%e5%8a%9f%e8%83%bd%e6%8a%91%e5%88%b6%e4%ba%ba%e7%be%a4%e6%96%b0%e5%86%a0%e7%97%85%e6%af%92%e6%84%9f%e6%9f%93%e6%8c%87%e5%af%bc","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=23537","title":{"rendered":"[JAMA\u533b\u5b66\u65b0\u95fb]\uff1a\u514d\u75ab\u529f\u80fd\u6291\u5236\u4eba\u7fa4\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u6307\u5bfc\u610f\u89c1\u66f4\u65b0"},"content":{"rendered":"\n

Medical News in Brief <\/p>\n\n\n\n

February 8, 2023<\/p>\n\n\n\n

Updated COVID-19 Guidance for People Who Are Immunocompromised<\/h1>\n\n\n\n

Emily Harris<\/h3>\n\n\n\n

JAMA. <\/em>Published online February 8, 2023. doi:10.1001\/jama.2023.1176<\/h3>\n\n\n\n

In late January, the US Food and Drug Administration announced that Evusheld (the combined monoclonal antibodies tixagevimab and cilgavimab) is not currently authorized for emergency use<\/a> because it\u2019s likely ineffective against more than 90% of SARS-CoV-2 variants now circulating in the US. Evusheld had been used as COVID-19 preexposure prophylaxis among certain patients who are immunocompromised.<\/p>\n\n\n\n

\"\"\/<\/figure>\n\n\n\n

In light of this change, the Centers for Disease Control and Prevention (CDC) released new recommendations<\/a> for people who are moderately or severely immunocompromised. Up-to-date vaccination, including with the bivalent booster, remains the best option for preventing infection and serious illness, according to the authors from the CDC COVID-19 Emergency Response Team. The report emphasized the importance of wearing an N95 mask, improving indoor ventilation, having a personal COVID-19 action plan, and other strategies.<\/a><\/p>\n\n\n\n

\u201cPersons who are immunocompromised should discuss a treatment plan with their doctor and identify which COVID-19 treatment would be best for them,\u201d the authors wrote. \u201cSome persons with COVID-19 who are immunocompromised or receiving immunosuppressive treatment might benefit from a convalescent plasma treatment.\u201d<\/p>\n\n\n\n

\"\"\/<\/figure>\n","protected":false},"excerpt":{"rendered":"

Medical News in Brief  February 8, 2023 […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23537"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23537"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23537\/revisions"}],"predecessor-version":[{"id":23540,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/23537\/revisions\/23540"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23537"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23537"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23537"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}